Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $19.79 million. The enterprise value is $9.82 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 60.89 million shares outstanding. The number of shares has increased by 11.72% in one year.
| Current Share Class | 60.89M |
| Shares Outstanding | 60.89M |
| Shares Change (YoY) | +11.72% |
| Shares Change (QoQ) | +14.45% |
| Owned by Insiders (%) | 5.08% |
| Owned by Institutions (%) | 12.38% |
| Float | 54.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.44 |
| Forward PS | 16.87 |
| PB Ratio | 0.39 |
| P/TBV Ratio | 1.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 19.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.81 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -62.12% and return on invested capital (ROIC) is -41.33%.
| Return on Equity (ROE) | -62.12% |
| Return on Assets (ROA) | -37.92% |
| Return on Invested Capital (ROIC) | -41.33% |
| Return on Capital Employed (ROCE) | -86.56% |
| Revenue Per Employee | $3,848 |
| Profits Per Employee | -$243,799 |
| Employee Count | 132 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | -1.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.82% in the last 52 weeks. The beta is 1.15, so Co-Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -67.82% |
| 50-Day Moving Average | 0.40 |
| 200-Day Moving Average | 0.37 |
| Relative Strength Index (RSI) | 45.29 |
| Average Volume (20 Days) | 3,502,629 |
Short Selling Information
The latest short interest is 2.41 million, so 3.96% of the outstanding shares have been sold short.
| Short Interest | 2.41M |
| Short Previous Month | 111,948 |
| Short % of Shares Out | 3.96% |
| Short % of Float | 4.46% |
| Short Ratio (days to cover) | 0.37 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $507,892 and -$32.18 million in losses. Loss per share was -$0.97.
| Revenue | 507,892 |
| Gross Profit | 172,843 |
| Operating Income | -35.53M |
| Pretax Income | -33.33M |
| Net Income | -32.18M |
| EBITDA | -34.33M |
| EBIT | -35.53M |
| Loss Per Share | -$0.97 |
Full Income StatementBalance Sheet
The company has $11.44 million in cash and $1.47 million in debt, giving a net cash position of $9.97 million or $0.16 per share.
| Cash & Cash Equivalents | 11.44M |
| Total Debt | 1.47M |
| Net Cash | 9.97M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 39.83M |
| Book Value Per Share | 0.83 |
| Working Capital | 10.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$31.17 million and capital expenditures -$641,065, giving a free cash flow of -$31.81 million.
| Operating Cash Flow | -31.17M |
| Capital Expenditures | -641,065 |
| Free Cash Flow | -31.81M |
| FCF Per Share | -$0.52 |
Full Cash Flow StatementMargins
| Gross Margin | 34.03% |
| Operating Margin | -6,995.70% |
| Pretax Margin | -6,562.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.72% |
| Shareholder Yield | -11.72% |
| Earnings Yield | -162.61% |
| FCF Yield | -160.74% |
Analyst Forecast
The average price target for Co-Diagnostics is $3.00, which is 823.08% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.00 |
| Price Target Difference | 823.08% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of -1.69 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.69 |
| Piotroski F-Score | 1 |
